Wits Clinical Research | WCR Chris Hani Baragwanath Clinical Trial Site

Research site

(Unclaimed)

Location

26 Chris Hani Road, Johannesburg, Guateng, South Africa

Site insights

Top conditions

Top treatments

Relamorelin

Semaglutide

INCB099280

PF-00547659

Sacituzumab

Sitagliptin

Ziltivekimab

Enzalutamide

PF-00489791

Pemafibrate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

14 of 32 total trials

A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the...

Active, not recruiting

Melanoma

Drug: Binimetinib

Drug: Encorafenib

A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation (HERMES)

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling

Heart Failure

Drug: Placebo

Drug: Ziltivekimab

A Study Evaluating the Efficacy and Safety of Oral Etrasimod in the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease (CULTIVATE)

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Enrolling

Crohn's Disease

Drug: Placebo

Drug: Etrasimod

A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Cell Carcinoma

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous S...

Active, not recruiting

Cutaneous Squamous Cell Carcinoma

Drug: INCB099280

A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Immune Checkpoint Inhibitor Naive

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumor...

Active, not recruiting

Advanced Solid Tumor

Drug: INCB099280

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer (VERITAC-2)

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Active, not recruiting

Advanced Breast Cancer

Drug: ARV-471

Drug: Fulvestrant

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with...

Active, not recruiting

Breast Cancer

Solid Tumors

Drug: PF-07104091 + PF-07220060 + letrozole dose expansion

Drug: PF-07220060 + PF-07104091 combination dose escalation

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants...

Active, not recruiting

Melanoma

Renal Cell Carcinoma (RCC)

Drug: INCB 99280 with Ipilimumab

Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer (POD1UM-304)

The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metast...

Active, not recruiting

Metastatic Nonsquamous Non-Small Cell Lung Cancer

Metastatic Squamous Non-Small Cell Lung Cancer

Drug: Placebo

Drug: Paclitaxel

Locations recently updated

Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH) (ESSENCE)

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Active, not recruiting

Non-alcoholic Steatohepatitis

Drug: Placebo

Drug: Semaglutide

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07)

The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer...

Active, not recruiting

Locally Advanced or Unresectable Metastatic Breast Cancer

Stage IV Breast Cancer

Drug: Paclitaxel

Drug: Capecitabine

Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer (ASCENT-03)

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of phy...

Enrolling

Triple Negative Breast Cancer

PD-L1 Negative

Drug: Sacituzumab Govitecan-hziy

Drug: Paclitaxel

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC (TALAPRO-2)

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of tal...

Active, not recruiting

mCRPC

Drug: Talazoparib with enzalutamide

Drug: Placebo with enzalutamide

ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling

Chronic Kidney Disease

Inflammation

Drug: Placebo (Ziltivekimab B)

Drug: Placebo (Ziltivekimab C)